Stem-like Cells Traffic From Heart Ex Vivo, Expand In Vitro, and Can Be Transplanted In Vivo

Steele, Ann; Jones, Olcay Y.; Gök, Faysal; Marikar, Yasmin; Steele, Peter; Chamizo, Wilfredo; Scott, Margie A.; Boucek, Robert J.

doi:10.1016/j.healun.2005.02.001

Cited by 21 publications

(42 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The final level of Y-chromosome positive cells seemed to be reached already shortly after transplantation and not to increase further after longer periods of time. A similar observation was made by Minami et al 27 This suggests that differentiation of bone marrow-derived stem cells does take place, but that these cells are either short lived and are possibly replaced by stem cells from the heart itself (organ-specific stem cells 28 ), or that the BM-derived stem cells only enter the heart under particular circumstances and then remain stable at that level. Another explanation may be the reduced circulation of progenitor cells due to the immunosuppression.…”

Section: Discussionsupporting

confidence: 61%

Stem cell-derived cardiomyocytes after bone marrow and heart transplantation

Weger

Verbrugge

Bruggink

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Cardiomyocytes are a stable cell population with only limited potential for renewal after injury. Tissue regeneration may be due to infiltration of stem cells, which differentiate into cardiomyocytes. We have analysed the influx of stem cells in the heart of patients who received either a gender-mismatched BMT (male donor to female recipient) or a gender-mismatched cardiac transplant (HTX; female donor to male recipient). The proportion of infiltrating cells was determined by Y-chromosome in situ hybridization combined with immunohistochemical cell characterization. In BM transplanted patients and in cardiac allotransplant recipients, cardiomyocytes of apparent BM origin were detected. The proportions were similar in both groups and amounted up to 1% of all cardiomyocytes. The number of stem cell-derived cardiomyocytes did not alter significantly in time, but were relatively high in cases where large numbers of BMderived Y-chromosome-positive infiltrating inflammatory cells were present. The number of Y-chromosome-positive endothelial cells was small and present only in small blood vessels. The number of BM-derived cardiomyocytes in both BMT and HTX is not significantly different between the two types of transplantation and is at most 1%.

show abstract

Section: Discussionsupporting

confidence: 61%

Stem cell-derived cardiomyocytes after bone marrow and heart transplantation

Weger

Verbrugge

Bruggink

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…In healthy mice, stem cells migrate into myocardium after intrapericardial injection, but they preserve their immature morphology. Nevertheless, in the presence of vasculopathy, cell differentiation occurred (Steele et al, 2005). Furthermore, in pigs, a marked myocardial homing of cells was observed following MI (Branco et al, 2009).…”

Section: Figurementioning

confidence: 99%

Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology

Jadczyk

Faulkner

Madeddu

2013

British J Pharmacology

View full text Add to dashboard Cite

Regenerative medicine holds great promise as a way of addressing the limitations of current treatments of ischaemic disease. In preclinical models, transplantation of different types of stem cells or progenitor cells results in improved recovery from ischaemia. Furthermore, experimental studies indicate that cell therapy influences a spectrum of processes, including neovascularization and cardiomyogenesis as well as inflammation, apoptosis and interstitial fibrosis. Thus, distinct strategies might be required for specific regenerative needs. Nonetheless, clinical studies have so far investigated a relatively small number of options, focusing mainly on the use of bone marrow-derived cells. Rapid clinical translation resulted in a number of small clinical trials that do not have sufficient power to address the therapeutic potential of the new approach. Moreover, full exploitation has been hindered so far by the absence of a solid theoretical framework and inadequate development plans. This article reviews the current knowledge on cell therapy and proposes a model theory for interpretation of experimental and clinical outcomes from a pharmacological perspective. Eventually, with an increased association between cell therapy and traditional pharmacotherapy, we will soon need to adopt a unified theory for understanding how the two practices additively interact for a patient's benefit. LINKED ARTICLESThis article is part of a themed section on Regenerative Medicine and Pharmacology: A Look to the Future. To view the other articles in this section visit http://dx

show abstract

“…Again, these cells seemed to be able to proliferate and to regenerate infarcted myocardium. In an interesting experiment, Steele et al [2005] isolated and expanded c-kit pos Sca-1 pos CD34 neg cells from myocardium of EGFPexpressing mice. When these cells were injected into the pericardial space of healthy GFP neg mice, they migrated throughout the heart but retained a primitive undifferentiated morphology.…”

Section: C-kitmentioning

confidence: 99%

A heart full of stem cells: the spectrum of myocardial progenitor cells in the postnatal heart

Stamm

Choi

Nasseri

et al. 2009

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

Influencing cellular regeneration processes in the heart has been a long-standing goal in cardiovascular medicine. To some extent, this has been successful in terms of vascular regeneration as well as intercellular connective tissue remodeling processes. Several components of today's routine heart failure medication influence endothelial progenitor cell behavior and support collateral vessel growth in the heart, or have been shown to prevent or reverse fibrosis processes. Cardiomyocyte regeneration, however, has so far escaped therapeutic manipulation strategies. Delivery of exogenous cells of bone marrow origin to the human myocardium may improve heart function, but is not associated with relevant neomyogenesis. However, accumulating evidence indicates that the myocardium contains resident cardiac progenitor cells (CPC) that may be therapeutically useful. This notion indeed represents a paradigm shift but is still controversial. The purpose of this review is to summarize the rapidly expanding current knowledge on CPC, and to assess whether it may be translated into solid therapeutic concepts.

show abstract

Stem-like Cells Traffic From Heart Ex Vivo, Expand In Vitro, and Can Be Transplanted In Vivo

Cited by 21 publications

References 23 publications

Stem cell-derived cardiomyocytes after bone marrow and heart transplantation

Stem cell-derived cardiomyocytes after bone marrow and heart transplantation

Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology

A heart full of stem cells: the spectrum of myocardial progenitor cells in the postnatal heart

Contact Info

Product

Resources

About